相关实验视频
Updated: Sep 17, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.8K
探索糖尿病前期的营养药物解决方案:关于巴纳巴和皮科林酸盐影响的叙事综述
G Derosa1, P Maffioli, A D'Angelo
1Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. giuseppe.derosa@unipv.it.
概括
皮科林酸盐 (CrP) 和巴纳巴叶提取物通过改善血糖控制,在治疗糖尿病前期表现有前途. 结合这些营养保健品可能会带来协同效益,可能会延迟2型糖尿病的发病.
科学领域:
- 代谢健康 代谢健康
- 营养学科学 营养学科学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病前期意味着葡萄糖控制受损,这是2型糖尿病 (T2D) 的前体.
- 早期干预对于预防T2D进展和并发症至关重要.
- 营养药物因其在新陈代谢调节方面的潜力而受到探索.
研究的目的:
- 审查皮科林酸盐 (CrP) 和巴纳巴叶提取物的代谢作用.
- 评估它们在改善糖尿病前期血糖控制方面的有效性.
- 探索CrP和巴纳巴提取物结合的潜在协同效应.
主要方法:
- 对CrP和巴纳巴叶提取物进行的临床前和临床研究的综述.
- 分析它们对胰岛素敏感性,葡萄糖水平和脂质概况的影响.
- 检查研究的研究,研究CrP和巴纳巴提取物的组合.
主要成果:
- CrP增强了胰岛素敏感性,降低了禁食血葡萄糖和HbA1c.
- 富含冠酸的巴纳巴提取物表现出胰岛素敏感性和降糖作用.
- 一项单一的研究表明,CrP和巴纳巴提取物在糖尿病前期的结合有积极的结果.
结论:
- 和巴纳巴叶提取物显示出作为糖尿病前期的补充疗法的潜力.
- 结合这些营养品可能为血糖控制提供协同效益.
- 需要进一步的研究来证实组合治疗的疗效.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269
Hormones Regulating Blood Glucose
4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Diabetes: Management and Pharmacotherapy
408
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
408

